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ABSTRACT 
Background: There is paucity of data from randomised controlled treatment trials 
in childhood arterial ischaemic stroke. Our objectives were to identify and plan a 
trial through use of a Delphi consensus process. 
 
Methods: The Delphi panel consisted of Australian, New Zealand and European 
paediatric neurologists with an interest in childhood stroke. Four rounds were 
conducted using a REDCap web based application; the first consisted of open 
ended questions, the second evaluated agreement for the most important trial, 
and the third and fourth reached consensus on design. 
 
Results: 47/66 neurologists answered the first round. Eight areas of research for 
important and feasible trials were identified. In the second round 43 ranked the 
3 highest rated trials: Aspirin versus aspirin plus steroids in focal arteriopathy 
(n=31), (ii) heparin versus aspirin (n=6) and (iii) heparin versus aspirin versus 
modern anticoagulation (trial 3n=6). The third and fourth surveys reached 
consensus among 43/44 respondents on design of the highest ranked trial, and 
allowed agreement on inclusion / exclusion criteria, clinical / neuroimaging data 
and treatment protocols. 
 
Conclusion: The Delphi Consensus Process is an efficient method of identifying 
and planning paediatric stroke trials. An international multicentre trial is now in 
preparation. 
 
What this paper adds: 
 Example of a Delphi process to evaluate research questions and design for a research 
protocol  
 Most important and feasible study evaluated: Steroid Aspirin versus Aspirin alone in focal 
arteriopathies in childhood stroke  
 Suggestions on a design for such a study  
 Information on current treatment decisions in Europe and Australia/New Zealand 
 
Keywords 
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INTRODUCTION 
Childhood arterial ischaemic stroke (AIS) affects 1.6-2.12 per 100,000 
children per year1. There is a total burden for neonatal and childhood AIS 
of almost 100’000 children per year worldwide 2. There is almost complete 
lack of evidence concerning acute and secondary preventative treatment 
of childhood stroke, which is reflected by consensus based 
recommendations in guidelines3. Extrapolating treatment 
recommendations from adults may not be appropriate due to differences 
in stroke pathogenesis, most notably the absence of risk factors for 
atherosclerosis in children4. 
Mortality ranges from 7–28%, with death being caused by the stroke or 
the underlying disease1,4. There are high rates of morbidity in survivors 
with 50% of children having neurological deficits 5 and even higher rates 
of cognitive deficits6. Refining management of childhood stroke, based on 
evidence, therefore seems mandatory to minimise long term sequelae. 
The relative infrequency of childhood AIS necessitates multicentre 
international collaboration but there are substantial obstacles to 
conducting such trials.  
Planning interventional studies requires health professionals to agree and 
prioritise studies of highest clinical importance. The aims of the study 
were therefore, to identify the most important treatment trial, by 
conducting a Delphi consensus process among paediatric neurologists, and 
determine the most feasible study design across sites, based on majority 
agreement. 
The Delphi Consensus Process, developed in the 1950’s for forecasting 
technological developments, 7explores opinions among groups of people 
with common interests and experience. It is increasingly used in health 
care settings to reach agreement among clinicians 8 and lay persons9. 
Agreement is reached following two to four iterative questionnaires. Ten 
to 30 participants are considered adequate to produce reliable results.10 
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METHODS 
Participants were identified by searching Pubmed for corresponding 
authors of publications related to childhood stroke, , and/or by their 
participation in  a national /regional paediatric stroke network within 
Europe, Australia and New Zealand. Participants were contacted by email 
for the first round and asked whether they would be willing to participate 
in the Delphi process.  
There were two iterative rounds of questionnaires to reach consensus 
about the most important and feasible trial, followed by two rounds to 
design the trial (see supplemental information). A survey was also 
conducted of current diagnostic and treatment practice at participating 
institutions.  
Survey data were collected and managed using the REDCap (Research 
Electronic Data Capture) tools, a secure, web-based application designed 
to support data capture for research studies11. 
The first open questionnaire (supplemental information) asked 
participants to separately list the five most important and five most 
feasible clinical treatment trials. A feasibility score (5 points most feasible) 
was calculated. The second questionnaire (supplemental information) 
summarised results from the first questionnaire and asked participants to 
rank the three highest scoring trials from the first round, in terms of 
importance and feasibility. Participants were also asked about (i) 
willingness to enrol patients in the three study proposals, if the protocol 
deviated from normal clinical practice, and an optional choice (ii) of 
potential primary and secondary outcomes of interest for each trial. 
Specific outcomes offered included clinical or radiological recurrence, 
outcome at 6 weeks or 6 months,  evolution of vasculopathy or other 
outcome (free text). Finally, demographic data was collected on survey 
participants.  
Once consensus was achieved about the most important trial, input for a 
third and fourth survey was sought from specialists in other disciplines 
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relevant to the proposed trial (immunologists, endocrinologists, infection 
disease specialists, neuroradiologists, clinical trialists and biostatisticians). 
The third round summarised results of the second round. This was 
followed by questions to reach consensus on definition of focal cerebral 
arteriopathy and the most pragmatic study design across sites, including 
survey of current practice, inclusion/exclusion criteria, clinical data 
elements to be collected, minimal imaging requirements for diagnosis, 
treatment regimes, follow up imaging protocols, study end points 
andprimary and secondary outcome measures (supplemental 
information). The fourth round followed on questions about inclusion time 
to study entrance and  acyclovir treatment in the steroid arm 
(supplemental information). For the purposes of analysis major agreement 
was defined as 90% consensus, minimum agreement was defined as 80% 
consensus. 
RESULTS 
Sixty six potential survey participants were identified, of whom 47 
answered the first round of questions (42 the second, 43 the third and 44 
the fourth round); three declined involvement, email contact addresses 
for eight participants were incorrect and further contact was not possible. 
A further eight did not respond for unknown reasons. All except two 
participants were neuropaediatricians, balanced for gender and age; 
31/43 were working mainly in clinical practice and 12/43 as academic 
clinicians. Three quarters were involved in research and had experience 
with interventional trials. 48 answered at least two of the questionnaires: 
seven respondents had been first/senior authors on research papers about 
childhood stroke, another 14 had been first/senior authors on relevant 
research papers, and the remaining 27 were integrated into paediatric 
stroke networks (many co-authors on relevant research papers). 
The First Delphi Round 
Results of the first Delphi round are summarised in table 1. Trials focusing 
on childhood stroke were identified by 38 of participants. A few identified 
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neonatal AIS and sinus venous thrombosis (SVT) trials as being 
important. Other suggested trials for childhood stroke included long term 
secondary prevention in childhood stroke, treatment of epilepsy, 
heparinisation for SVT, general treatment approaches in neonatal stroke 
and effect of physiotherapy.  There were additional suggestions 
concerning risk factors, genetics, and diagnostic approaches.  One 
participant, who declined further involvement, was concerned about 
insufficient knowledge of childhood AIS pathophysiology to warrant 
treatment trials.  
The second Delphi round 
The second round questionnaire explored the most important and feasible 
studies identified by the first survey.  Participants  were asked to rank the 
three highest scoring trials from the first survey. 43 participants 
responded to the second questionnaire, but only 42 answers were 
available for some questions. A trial comparing aspirin plus 
corticosteroids, versus aspirin treatment alone, for stroke in focal cerebral 
arteriopathy (FCA) was identified as the most important and feasible trial 
(table 2). 
Willingness to include children in the trials, even if it deviated from normal 
clinical practice also favoured the aspirin and steroids versus aspirin trial 
(table 2). Fewer participants were willing to randomise patients to trials of 
antiplatelet versus anticoagulant therapy, prior to exclusion of cardiac and 
or dissection (14 and 18 participants respectively).  
There were four options for possible primary and secondary outcomes.  
Survey answers provided by 30 to 42 of participants about possible 
primary and secondary outcome are summarized in table 3.  The required 
80% level of consensus was not achieved for outcomes but there was 
greater than 50% agreement found for each trial (table 3). 
Demographic information on survey participants is summarised in table 4.  
The third Delphi round 
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The second survey suggested that a trial comparing aspirin to aspirin plus 
steroids in children with FCA had the highest ratings in terms of 
importance, feasibility and willingness to participate. The focus of the third 
survey, was therefore to determine current practice across sites, 
diagnostic definitions, baseline variables, outcomes of interest, and key 
requirements for conducting the trial. 
More than 90% consensus (agreement from at least 40/44 participants) 
was reached in the following areas.  
Study inclusion criteria and definition of FCA: (i) unilateral focal 
arteriopathy in ≤ 2 vessels affected with irregularity and/or stenosis, or 
occlusion on vascular imaging, (ii) acute infarction in the area of at least 
one affected vessel, (ii) age at stroke 6 months-18 years, (iii) no evidence 
of an underlying systemic disorder, (iv) informed consent obtained from 
parents. 
Study exclusion criteria: (i) secondary CNS angiitis, due to infections 
(meningitis, encephalitis), rheumatic or other systemic inflammatory 
disease, (ii) progressive large to medium vessel in childhood primary 
angiitis of the central nervous system (cPACNS), (iii) already on steroid 
treatment at presentation, (iv) congenital or acquired immunodeficiency 
and (iv) Moyamoya disease or syndrome. 
Presenting clinical variables to be collected: (i) medical history and 
neurological findings (using a predetermined case report form), (ii) vital 
observations as bodyweight, temperature, blood pressure, and (iii) stroke 
severity, using the pediatric NIH stroke score (pedNIHss).  
Minimal diagnostic imaging requirements prior to inclusion and at follow 
up: (i) diffusion weighted imaging (DWI) with apparent diffusion 
coefficient (ADC) maps, (ii) axial fluid attenuated inversion recovery 
(FLAIR), (iii) susceptibility weighted imaging (SWI) and (iv) arterial 3D 
time of flight (TOF) magnetic resonance (MRA) vascular imaging. 
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Treatment regimen for study patients: (i) aspirin or heparin treatment 
before enrolment to the study (on individual clinical decision), with 
inclusion into study: (ii) both treatment arms to receive 5mg/kg 
bodyweight (BW) aspirin daily (max 300mg/day), (iii) 5 days pulse of 
20mg/kg BW methylprednisolone (max 1g/day) for steroid arm, (iv) 
followed by a six-week tapering regime using oral prednisolone and (v) no 
need for stress test (assessing the pituitary adrenal axes) following 
tappering of steroids. 
More than 80% consensus (agreement from at least 35 participants) was 
reached for two questions. Thirty-nine agreed to enrolment within 4 days 
of admission; two suggested less than 4 days and two more than 4 days.  
Thirty-six participants agreed to first follow up imaging at three months, 
one suggested imaging at one month, and six at six months only.  
Consensus could not be reached for acyclovir treatment. Thirty (68%) 
participants felt that acyclovir was indicated prior to exclusion of varicella 
infection (positive CSF VZV PCR or antibodies, or serum IgM antibodies) in 
children with a history of exposure within six month prior to stroke 
diagnosis.  
The survey of current treatment practice for FCA revealed that all 
children were treated with corticosteroids in 9 centres (20%). Usage was 
a treatment option in the remaining 32 centres; corticosteroids were 
used if there were ongoing TIAs or recurrent strokes, despite aspirin in 
21 centres, or in cases with radiological or sonographic worsening of FCA 
in 30 centres. Eleven participants raised concerns that corticosteroid side 
effects may outweigh potential benefits. Vessel wall imaging was used to 
guide usage of corticosteroids at 26 centres. Acyclovir was used in 
combination with steroids in children with FCA at only 8 centres, 
whereas 31 centres prescribed acyclovir in cases with VZV positivity on 
CSF examination and or serology. Unfortunately, the question of how 
positive history of varicella would influence this decision was not asked. 
The Fourth Delphi Round 
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The fourth round was answered by 44 participants and reached majority 
agreement on reducing time to enrolment to 48 hours –two participants 
suggesting shorter, and two longer inclusion times. Consensus was also 
reached for use of acyclovir treatment in the steroid arm until exclusion 
of active infection by herpes and/varicella virus by PCR or antibodies in 
CSF and/or serum. 
 
DISCUSSION 
A study comparing aspirin plus corticosteroids to aspirin treatment alone 
was identified as the most important and feasible trial by the vast 
majority of respondents. Importantly the majority of respondents were 
also prepared to enrol patients even if this deviated from their normal 
clinical practice. Similar to the WEST Delphi that informed the design of 
the recently published ICISS trial investigating the treatment of infantile 
spasms 12, this Delphi process has provided useful information on 
current diagnostic protocols and treatment practice among a 
multinational group of paediatric neurologists, influencing the design of 
the proposed trial.  
 
The varied response in the first open questionnaire highlights the current 
lack of evidence for treatment of childhood stroke. Thrombolysis and 
mechanical thrombectomy were felt to be the most important trials, 
probably explained by the strong evidence for efficacy in adults13,14. 
However, there is great uncertainty about the efficacy of thrombolysis in 
childhood stroke because of the different aetiologies involved. 
Respondents felt that trials of thrombolysis and thrombectomy were not 
feasible, possibly reflecting concerns regarding long lead-time to 
diagnosis of arterial ischaemic stroke in children15. This is also reflected 
in the problems encountered by the TIPS trial, which despite preparing 
an in house emergency management protocol failed to recruit adequate 
numbers of patients 16. 
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A corticosteroid trial in FCA was identified as the most feasible and 
second most important trial. This was confirmed in the second round, 
with respondents willing to enrol subjects, even if the allocated 
treatment deviated from normal practice. 
Recent publications suggest an important role of inflammation and 
infection in childhood stroke 17. Herpes group viruses are the most 
common infectious agent in FCA, but there are other infectious triggers 
18,19.  Corticosteroids were already being used in the majority of centres 
by survey participants, although there was practice variation.   
 
Trials of antiplatelet versus anticoagulant therapies were considered to 
be less important and feasible. There is evidence in adults, that 
antiplatelet therapy is superior to anticoagulation in acute ischaemic 
stroke20. It is important to acknowledge, however, that arteriosclerosis, 
the major risk factor in adults is not a significant risk factor in children. 
Still, extrapolation of data on these treatment modalities to the 
childhood population is probably more reliable than for thrombolysis. In 
addition, trials of antiplatelet agents versus anticoagulants require large 
numbers to demonstrate a treatment effect. 
  
The third survey focused on study design. There was ≥90% consensus  
for inclusion criteria, with the exception of lag time to study entry. 
Discussion between participants brought high consensus in a fourth 
round for enrolment within 48 hours, which balances the need for early 
implementation of steroid treatment to reduce vascular inflammation 
against the need of time to complete diagnostic investigations prior to 
inclusion. It is particularly important for clinicians to exclude 
cardioembolic stroke and arterial dissection, because consensus based 
paediatric stroke guidelines suggest anticoagulation as the treatment of 
choice in both conditions 3  
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There was majority agreement for suggested exclusion criteria. The 
problem of recognising a progressive vasculopathy at initial 
presentation was discussed in free comments. For some conditions such 
as primary CNS angiitis, steroids are the treatment of choice. On the 
other hand the risk of steroids in non-inflammatory progressive 
arteriopathies such as Moyamoya, masquerading as a unilateral FCA 
were not rasied as a major concern. To decrease the risk even further, 
inclusion criteria were limited to unilateral FCA and additional secondary 
safety outcomes were chosen. 
  
There was more than 90% consensus for a minimum neuroimaging 
dataset. DWI/ADC maps are considered the gold standard to identify 
ischaemic lesions21, FLAIR images help determine timing of the lesion22, 
SWI for detection of haemorrhage, and time of flight MR angiography to 
assess vessel status. Some participants indicated that advanced 
imaging (perfusion and vessel wall imaging) could be performed at their 
centres, which will be important for the development of satellite 
neuroimaging studies. 
  
There was much discussion in the free text responses about the 
proposed treatment regimen, but once again majority agreement was 
reached in the third and fourth surveys for all questions. Aspirin dosage 
was chosen based on published consensus guidelines.3 Corticosteroid 
regimens and surveillance for side effects were chosen, based on 
dosage and formulation used in paediatric demyelinating and 
inflammatory disorders23. Published data suggests that serious side 
effects are rare with short duration high dose steroid regimens24. Expert 
advice from endocrinologists (FC) and neuroimmunologists (RD) agreed 
with the proposed treatment regime.  
 
Consensus on acyclovir treatment in steroid arm was reached in the 
fourth Delphi round. Varicella virus has been detected in the vessel wall 
13 
 
in post varicella vasculopathy and the arteriopathy is thought to be 
related to a reactivation of the inflammatory process.25 The Vascular 
Infectious Pediatric Stroke Groups (VIPS) study, however, suggests that 
arteriopathy might also be related to a primary infection by herpes 
group viruses19. A recent review on management of varicella 
arteriopathy 26 and also our survey revealed that antiviral therapy is 
given increasingly in FCA.  
 
There was only 80% agreement for timing of follow-up imaging at 3 and 
6 months respectively i.e. earlier imaging at 3 months to identify 
potential worsening versus 6 months only as a study endpoint. There 
were concerns that the protocol might entail extra anaesthesia in some 
children, but there is a strong argument that most of studies would be 
indicated clinically. Protocols on performing MR images without 
anaesthesia/sedation in children are available27. Insisting on only a 
limited imaging data set will facilitate MR imaging. 
  
Eight respondents suggested longer follow up than 6 months. However, 
recurrence and worsening of the arteriopathy peaks around 3 months 
after stroke 18 and neurological outcome at 6 months has been shown to 
accurately reflect longterm outcome6. Therefore, we believe a primary 
endpoint at 6 months with a secondary endpoint at 12 months is 
justified. 
The feasibility of such a study depends on the willingness of clinicians to 
enrol patients. This Delphi survey suggests that 41/43 participants would 
be willing to include patients. Using time to recovery as the primary 
outcome and postulating an effect size of 0.5, a sample size  calculation 
by a generic approach suggests that 128 children would be needed in a 
trial (90% power, alphalevel of 0.05). Using known incidence data, we 
estimate to recruit 200 children over three years from five existing 
stroke networks in Europe/Australasia. Participation of other centres 
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would accelerate recruitment and possibly shorten the duration of any 
proposed trial.  
 
This study has limitations. In particular there was a geographical bias. 
More centres from Great Britain, Switzerland and Australia were 
involved, which may reflect the presence of established paediatric stroke 
research networks but may also reflect the nationality of the authors1,6.  
There were significantly more European than Australian participants, but 
this is likely explained by larger population in Europe than Australia. 
There were no participants from either North or South America and 
therefore the generalizability of the consensus views expressed here only 
applies to Europe and Australasia. 
The Delphi process is a method of obtaining consensus among experts. 
The process will not, per se, determine the feasibility of a proposed 
study. However, obtaining consensus about definitions and possible 
study protocols will increase the likelihood of the success of any future 
trial and the acceptance of any results that the trial produces amongst 
the relevant expert community.  
 
 
In conclusion, the Delphi consensus process is a feasible and valuable 
instrument to survey current practice and to engage paediatric 
neurologists in the design of a paediatric stroke treatment trial which is 
acceptable to clinical researchers. The Delphi suggests that a randomised 
trial comparing aspirin and steroids to aspirin alone is the most important, 
feasible and acceptable childhood AIS trial. More than 90% consensus was 
reached for almost all components of the proposed trial, increases the 
likelihood of successful completion.  
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Tables 
Table 1: Most important clinical trials in arterial childhood stroke 
Topics of possible 
studies 
Most 
important* 
2nd most 
important* 
3-5th 
important* 
Feasibility 
** 
 
Immunosuppressive 
treatment in FCA 
9 4 6 3.89 
Aspirin versus Heparin 3 12 13 3.25 
Aspirin versus different 
anticoagulants 
5 6 11 3.5 
Thrombolysis (ia, iv)  17 7 5 2 
Thrombectomy 2 2 5 2.3 
Other Treatments  2 4 24 3.3 
Non treatment trials in 
childhood AIS 
2 4 15 3.69 
Treatment in neonatal 
stroke and/or SVT 
1 7 12 3.35 
FCA focal cerebral arteriopathy. AIS arterial ischaemic stroke. SVT sinus 
venous thrombosis 
* number of participants ranking the topic in this level 
** Feasibility ranked by participants (ranking from 1-5: 5 being very 
feasible and 1 being unfeasible) 
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Table 2: Importance and willingness for inclusion into the 3 most 
important trials 
Trial most 
important 
2nd most 
important 
least 
important 
willingness 
for inclusion 
Aspirin and steroids 
versus aspirin alone 
(n=43) 
31 5 7 41 
Aspirin versus Heparin 
(n=42) 
6 19 17 25 
Aspirin versus Heparin 
versus modern oral 
AC (n=43) 
6 19 18 21 
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Table 3: Choices for primary and secondary outcomes 
 Primary outcome /secondary outcome  
suggested for the 3 different trials  
 Aspirin /  
Aspirin -
Steroids 
Aspirin / 
Heparin 
Aspirin / 
Heparin / 
modern AC 
    
Clinical and/or 
radiological stroke 
recurrence within 6 
weeks 
13 /17 17/13  17 /13  
Clinical and/or 
radiological stroke 
recurrence within 6 
months 
26 /16  18 /20  19 /20  
Clinical outcome after 6 
months 
14 /23  12 /28  11 /27  
Normalisation of 
vasculopathy 
9 /27  6 /24  7 /23 
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Table 4: Demographic information on survey participants 
Speciality Neuropaediatrics 41 
 Other 2 
Sex female- male 21:21 
Age groups 35-44 years 13 
 45-54 years 15 
 55-65 years 13 
 > 65 years 1 
Working place Australia New Zealand 9 
 Europe 34 
Working area regional hospital 4 
 tertiary care hospital 12 
 university hospital 27 
Working area mainly clinical 31 
 mainly research 0 
 mix 12 
Involvement in 
research 
currently  31 
 past /present participation in  
multicentre treatment trials 
31 
Position  training  1 
 staff member 25 (7 part time) 
 head of division 17 
 
 
Supplementum 
Questionnaires 1-4 of Delphi Survey 
 
 
